DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Top related locs:
Top related orgs:
& $ - 1

Search resuls for: "David Ricks"


11 mentions found


☆ Eli Lilly investors spooked by weak Mounjaro sales, but it's the obesity drug approval that will unlock its value
  + stars: | 2023-02-02 | by ( Christina Cheddar Berk | ) www.cnbc.com   time to read: +5 min
Lilly said slightly more than 50% of commercial and Part D subscribers have access to the drug via their insurance plans. But new classes of weight loss medications are helping to change this mindset. Still, legislation will be necessary to get coverage of Mounjaro for obesity and overweight treatment by Medicare plans. By law, these plans are banned from paying for weight loss medications. Wegovy and Mounjaro One encouraging sign: Lilly competitor Novo Nordisk has gained access to more than 80% of insurance company formularies for their obesity treatment, Wegovy.
☆ Eli Lilly CEO weighs in on Q4 revenue miss
  + stars: | 2023-02-02 | by ( ) www.cnbc.com   time to read: 1 min
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailEli Lilly CEO weighs in on Q4 revenue missEli Lilly CEO David Ricks joins 'Squawk Box' to discuss the company's change in guidance, the outlook for the company's Diabetes drug, and Eli Lilly's manufacturing capacity of the new drug, Mounjaro.
☆ Eli Lilly's post-earnings decline is creating a buying opportunity for long-term investors
  + stars: | 2023-02-02 | by ( Kevin Stankiewicz | ) www.cnbc.com   time to read: +7 min
Eli Lilly (LLY) reported mixed fourth-quarter results Thursday morning, but we're looking through the stock's post-earnings sell-off because there's no change to the pharmaceutical giant's bright long-term potential. Bottom line There's definitely some noise surrounding Eli Lilly's results, including sales of its key diabetes drug Mounjaro. Eli Lilly began its rolling submission to the FDA in late 2022. None of them undercut the multiyear Eli Lilly investment story, making Thursday's stock sell-off an attractive buying opportunity. It is a "very complicated" process to make that kind of drug, Ricks said, so it cannot just scale up overnight.
☆ Eli Lilly's Alzheimer's drug hits a regulatory hurdle. But our belief in the stock isn't shaken
  + stars: | 2023-01-20 | by ( Kevin Stankiewicz | ) www.cnbc.com   time to read: +8 min
Eli Lilly 's (LLY) attempt to receive accelerated regulatory approval for its Alzheimer's drug donanemab has been rejected. Eli Lilly said it will keep working with the FDA to "evaluate the fastest pathway" for donanemab to reach patients. Indeed, analysts at Barclays wrote in a note to clients Thursday that "we now see [accelerated approval] off the table." LLY 1Y mountain Eli Lilly (LLY) 1-year performance "It's definitely not a thesis-breaker," Bank of America analyst Geoff Meacham told CNBC on Friday. David Ricks, CEO, Eli Lilly Scott Mlyn | CNBC
☆ Afternoon update: Soft-landing market rally, Alzheimer's drug approval, time to sell a winner
  + stars: | 2023-01-06 | by ( Jim Cramer Jeff Marks | Jim Cramer | Jeff Marks | ) www.cnbc.com   time to read: +3 min
If the Fed doesn't have to tighten as hard, many stocks are at levels you want to buy." Rival Alzheimer's drug approval good for Lilly, too JM: "Biogen is getting accelerated approval for that new Alzheimer's drug. [ Eli Lilly CEO] David Ricks says ... confidence in the Alzheimer's class is going to be good for them as well. Can't be greedy: We need to sell some EL JM: " Estee Lauder , what should we do about it?" As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade.
☆ We're increasing price targets on 3 of our stocks, including 2 crushing the boarder market
  + stars: | 2022-11-08 | by ( Jeff Marks | ) www.cnbc.com   time to read: +4 min
Following our price target changes on eight Club holdings last month, we're updating three more Tuesday to reflect their recent quarterly earnings reports and outlooks. It's also worth noting that we have not adjusted our Lilly price target since competitor Biogen (BIIB) reported positive topline results from a study to treat early Alzheimer's. Halliburton (HAL): Club price target increasing to $44 per share from $40 This update comes about two weeks after the oilfield services provider reported a stronger-than-expected third quarter . THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.
☆ Eli Lilly says some staff want to leave Indiana because of abortion ban, Financial Times reports
  + stars: | 2022-11-06 | by ( ) www.reuters.com   time to read: +1 min
Nov 6 (Reuters) - Some Eli Lilly and Co (LLY.N) employees have requested transfers from the drugmaker's Indiana operations after the U.S. state's lawmakers approved a bill that would ban most abortions there, the Financial Times reported on Sunday. Some staff had asked to relocate outside the state even though an Indiana judge has temporarily halted the ban, the Indiana-based pharmaceutical firm's chief executive David Ricks told the newspaper in an interview. His comments come after the Republican-controlled Indiana Senate passed a law in August banning most abortions. An Indiana judge blocked the state in September from enforcing the new law while Planned Parenthood and other healthcare providers challenge it in court. Eli Lilly did not provide details on how many staff have asked to move from Indiana, the FT said.
☆ Eli Lilly says some staff want to leave Indiana because of abortion ban - FT
  + stars: | 2022-11-06 | by ( ) www.reuters.com   time to read: +1 min
Nov 6 (Reuters) - Some Eli Lilly and Co (LLY.N) employees have requested transfers from the drugmaker's Indiana operations after the U.S. state's lawmakers approved a bill that would ban most abortions there, the Financial Times reported on Sunday. Some staff had asked to relocate outside the state even though an Indiana judge has temporarily halted the ban, the Indiana-based pharmaceutical firm's chief executive David Ricks told the newspaper in an interview. An Indiana judge blocked the state in September from enforcing the new law while Planned Parenthood and other healthcare providers challenge it in court. Ricks said the new restrictions had created challenges for people to come to work in Indiana and that if Eli Lilly wanted to attract and retain the best staff, it had to grow in other locations, the FT said. Eli Lilly did not provide details on how many staff have asked to move from Indiana, the FT said.
☆ 2 takeaways from our daily meeting: Stocks await Fed decision, Club earnings recap
  + stars: | 2022-11-02 | by ( Krystal Hur | ) www.cnbc.com   time to read: +3 min
Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. Fed decision ahead Quick takes on Club earnings 1. Fed decision ahead Stocks edged down Wednesday ahead of the Federal Reserve's decision on interest rate increases, set for this afternoon. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.
☆ What Cramer is watching Wednesday — Fed day, AMD signs of life, China hits Estee Lauder
  + stars: | 2022-11-02 | by ( Jim Cramer | ) www.cnbc.com   time to read: +5 min
While missing lowered expectations in the third quarter, Club holding AMD did see a year-over-year revenue growth. Club holding Estee Lauder (EL) beats on fiscal first-quarter earnings and matches on revenue. Club holding Devon Energy (DVN): Very strong quarter . Club holding Humana (HUM) sees membership growth. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade.
Organizations: & $
☆ Eli Lilly's guidance cut is about the strong dollar, not weakening fundamentals, CEO says
  + stars: | 2022-11-01 | by ( Kevin Stankiewicz | ) www.cnbc.com   time to read: +5 min
Eli Lilly — which generates about 40% of its sales overseas — largely attributed the guidance cut to the strong U.S. dollar. With three quarters already reported, Eli Lilly now expects full-year sales to range between $28.5 billion to $29 billion and adjusted per-share earnings between $7.70 to $7.85. New diabetes drug off to great start One of our biggest reasons for liking Eli Lilly is the company's new type 2 diabetes drug that's also shown promise as an obesity treatment . The drug is similar to one that Eli Lilly is working to treat the most common form of dementia. David Ricks, CEO, Eli Lilly Scott Mlyn | CNBC
<< prev 2 next >>
Total: 11